Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs |
| |
| Authors: | Korbinian Pieper Tibor Schuster Olivier Levionnois Ulrike Matis Alessandra Bergadano |
| |
| Affiliation: | 1. Department of Small Animal Surgery, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany;2. Department of Medical Statistics and Epidemiology, Technische Universität München, Munich, Germany;3. Department of Clinical Veterinary Medicine, Division of Anaesthesiology, Vetsuisse-Faculty, University of Berne, Switzerland;1. Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway;2. Small Animal Teaching Hospital, University of Liverpool, Liverpool, UK;3. Department of Production Animal Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway;4. Department of Animal Sciences, University of Wisconsin-Madison, Madison, WI, USA;5. Animal Health and Welfare Branch, Veterinary Inspectorate and Force Health Protection, Norwegian Armed Forces Joint Medical Services, Sessvollmoen, Norway;1. Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;2. Biologics and Pharmaceutical Science, H. Lundbeck A/S, Valby, Denmark;3. Process Chemistry, H. Lundbeck A/S, Valby, Denmark;4. Bioneer: FARMA, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | To assess the antinociceptive efficacy of transdermal (TD) buprenorphine (B) in dogs, a prospective, positive-controlled experimental study was performed in 10 healthy Beagles. In an open label crossover design, the dogs initially received intravenous B (IVB, 0.02 mg kg?1) as a positive control, followed by TDB (52.5 μg h?1) 4 months later. Blood was collected at regular intervals for determination of the plasma concentrations of B ([B]) and its metabolite norbuprenorphine. The antinociceptive efficacy was assessed using thermal and mechanical models of nociception. The peak concentration [B] was 1.54 ng mL?1 (±1.98) 60 h after TDB application, although three dogs had no measurable [B] after TDB. Maximum thermal threshold (TT) was 52.6 °C (±0.48) at 1 h after IVB administration and 51.63 °C (±1.01) 72 h after TDB application. The significant increase in TT indicated that effective antinociception was achieved beyond 36 h after the application of TDB, lasting until patch removal. There was hysteresis between [B] and the antinociceptive effect. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
